First tour at the future office. A near 1000 sqm facility with R&D, lab and clinical trail unit will be out future work place.
Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
On September 10, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo